جستجوی استاد راهنمای دانشگاهی

• Cardiovascular Disease
• Coronary Microvascular Dysfunction
• Invasive Coronary Function Testing
• +۳ مورد دیگر

Nida Latif is a Research Fellow in the Department of Internal Medicine at Yale School of Medicine. Her work focuses on understanding coronary microvascular dysfunction and ischemic heart disease in patients with nonobstructive coronary arteries, particularly in women. She is a key contributor to the DISCOVER INOCA multicenter registry, evaluating invasive coronary function testing protocols and diagnostic strategies. Her research integrates clinical, anatomical, and physiological data to improve diagnostic accuracy and patient outcomes. Key areas of investigation include coronary vasoreactivity testing, risk factor analysis in ischemic syndromes, and the impact of diabetes on angina pathophysiology. Latif's publications highlight advancements in coronary flow reserve measurement, comparison of diagnostic modalities (e.g., PET vs thermodilution), and the clinical utility of vessel-specific analysis. Her work emphasizes translational outcomes, bridging basic science insights with clinical practice improvements. While no specific awards are listed, her contributions to high-impact clinical registries and peer-reviewed publications reflect her active role in advancing cardiovascular medicine.

• Heart Failure
• Cardiovascular Immunology
• Cardiac Inflammation
• +۳ مورد دیگر

Xiaochen He serves as an Instructor in the Department of Physiology & Biophysics at the University of Mississippi Medical Center's School of Medicine, where he focuses on cardiovascular research and teaching within this foundational medical science department. His research program centers on the intersection of cardiac pathophysiology and immunometabolism, with core interests including: Mechanisms of immune-mediated cardiac inflammation in heart failure Role of T cell subsets (Th17, γδ T, CD8+) in pressure overload models Molecular regulation by IL-12 family cytokines and metabolic enzymes (TIGAR, SIRT3) Endothelial dysfunction in cardiac hypertrophy and failure progression Therapeutic interventions targeting inflammatory pathways Analysis of Dr. He's recent publications (2022-2025) reveals a concentrated research trajectory investigating how specific immune pathways drive heart failure progression. His work consistently employs genetic mouse models to demonstrate that IL-12β inhibition, TIGAR deficiency, and selenium supplementation attenuate cardiac inflammation and dysfunction, while CD8+ T cell metabolic reprogramming exacerbates disease. Key discoveries include GPR174's role in Th17 differentiation and NK1.1 signaling's contribution to cardiopulmonary inflammation, establishing critical immune-metabolic axes in heart failure pathogenesis. No scientific awards were documented in the available profile information. Current departmental records indicate no graduate students are formally listed under Dr. He's mentorship, and no research grants are specified in the public profile. Details regarding laboratory infrastructure, research teams, or collaborative networks were not provided in the available institutional documentation.

• Cardiovascular System Modelling
• Biosignal Processing
• Wearable Nanosensors
• +۵ مورد دیگر

Haipeng Liu is an Assistant Professor in the Centre for Intelligent Healthcare at Coventry University. His research focuses on cardiovascular system modeling, biosignal processing, wearable nanosensors, and AI-driven diagnostics. He has supervised over 100 research outputs and holds editorial roles in journals like Frontiers in Physiology and Electronics . His work bridges clinical needs with technological innovation, particularly in healthcare technology and cardiovascular diagnostics. Research Interests: Computational modeling of cardiovascular systems, AI-enhanced diagnostics, wearable sensors, and medical imaging. Key Awards: British Heart Foundation Travel Award (2019), First Prize in National Mathematics Competition (2011). Collaborations: Active in global research networks, including the World Stroke Organization. His recent work emphasizes machine learning applications in cardiology and stroke diagnostics, with publications in Physics of Fluids , European Journal of Radiology , and Frontiers in Genetics . He is a sought-after advisor for PhD students exploring healthcare technology.

• Cardiovascular Epidemiology
• Sex and Gender Differences in Cardiovascular Disease
• Comparative Effectiveness Research
• +۵ مورد دیگر

Louise Pilote, MD, MPH, PhD is Professor of Medicine in the Department of Medicine, Division of Internal Medicine , McGill University , and Senior Scientist in the Cardiovascular Health Across the Lifespan Program at the Research Institute of the McGill University Health Centre (RI-MUHC) , Montréal, Canada. Education: Louise Pilote holds the combined degrees of MD, MPH, and PhD, reflecting advanced clinical, public-health and research training that underpins her translational work. Research Focus: Internationally recognized pioneer in sex- and gender-based cardiovascular epidemiology , developing novel gender indices to disentangle biological (sex) and sociocultural (gender) determinants of cardiovascular outcomes. Leads the multinational GOING-FWD consortium (Gender Outcomes International Group to Further Well-being Development), integrating sex/gender analytics across 30 cohorts totaling 30 million patients with chronic diseases. Authority on comparative effectiveness and pharmacoepidemiology leveraging administrative “Big Data”, clinical registries, and advanced biostatistical/machine-learning methodologies. Current clinical-translational projects include imaging-based diagnosis of coronary microvascular dysfunction , a condition disproportionately affecting women. Scientific Impact & Awards: While formal awards are not enumerated in the supplied text, Dr Pilote’s sustained leadership as senior author on major Canadian and international cardiovascular guidelines, her role in founding the GOING-FWD network, and her extensive publication record (398 PubMed-indexed articles, 1988-2025) collectively constitute significant peer recognition. Students & Mentoring: Specific trainee names are not provided in the text; however, as Professor at McGill and Senior Scientist at RI-MUHC she supervises graduate students, clinical research fellows, and post-doctoral researchers in cardiovascular epidemiology, data science, and gender medicine. Laboratories & Teams: Dr Pilote heads the cardiovascular epidemiology research group within the Centre for Outcomes Research and Evaluation (CORE) at RI-MUHC, coordinating a multi-disciplinary team of biostatisticians, data scientists, clinician-scientists, and trainees.

Bülent DEMİRمشاهده پروفایل

استاد

• Cardiovascular Medicine
• Coronary Artery Disease
• Metabolic Syndrome
• +۳ مورد دیگر

Prof. Dr. Bülent DEMİR serves as Head of the Department of Cardiology at Istanbul Medipol University International Faculty of Medicine since 2010. His clinical career spans multiple prestigious institutions including Ankara High Specialization Training Hospital, Bakırköy Dr. Sadi Konuk Hospital, and Turkish Hospital in Doha-Qatar. Fluent in English, he maintains active clinical practice at Bagcilar Medipol Mega University Hospital. His research focuses on inflammatory mechanisms in cardiovascular disease , particularly examining biomarkers like IL-17A, zonulin, and epicardial adipose tissue in conditions including metabolic syndrome, coronary artery disease, and cardiac syndrome X. Recent work explores connections between endocrine disorders (thyroid dysfunction, gestational diabetes) and cardiovascular outcomes. Analysis of his 15 most recent publications reveals strong emphasis on multimarker approaches to understanding vascular inflammation, with significant contributions to identifying novel angiographic phenomena like contrast layering clearance. His work bridges basic vascular biology (endothelial cell cultures, statin effects) with clinical cardiology applications. Prof. DEMİR actively supervises research with frequent collaborations across cardiology, endocrinology, and nephrology domains. His team has presented findings at major international forums including ESC Congress and Turkish Cardiology Congresses, though specific grant funding details are not documented in available materials.

• Cardiovascular Medicine
• Coronary Artery Disease
• Fractional Flow Reserve
• +۶ مورد دیگر

Dr. Keith Oldroyd is an Honorary Professor at the University of Glasgow's School of Cardiovascular & Metabolic Health. His research focuses on coronary physiology, myocardial infarction, and interventional cardiology, with a particular emphasis on fractional flow reserve (FFR) and coronary microvascular dysfunction. He leads major clinical trials such as CorMicA and FAMOUS-NSTEMI, assessing diagnostic and therapeutic strategies in coronary artery disease. Key contributions include advancing understanding of coronary microvascular dysfunction, optimizing PCI outcomes, and evaluating the clinical impact of influenza vaccination post-MI. Collaborations with institutions globally highlight interdisciplinary work in drug-eluting stents, biomaterials, and cardiovascular imaging. Over 150 peer-reviewed publications (2001–2024) Principal Investigator for CorMicA trial Leadership in Glasgow PRAMI and EVOLVE 48 studies Labs/Teams: Active in translational cardiology research at the Golden Jubilee National Hospital and University of Glasgow's cardiovascular imaging and intervention teams.

• Cardio-Oncology
• Air Pollution and Cardiovascular Disease
• Space Medicine
• +۵ مورد دیگر

Kazuaki Negishi is a Professor of Medicine and Head of the Discipline of Medicine at Sydney Medical School Nepean, University of Sydney's Faculty of Medicine and Health. He holds adjunct professorships at the University of Tasmania and is a board-certified cardiologist in Japan and Australia. His expertise spans cardio-oncology, air pollution-cardiovascular links, space medicine, and advanced imaging. Clinically, he practices at Nepean Hospital and previously led the Echo lab at Royal Hobart Hospital. He completed his MD and PhD in Japan, with additional training at Cleveland Clinic, USA. Research interests include cardiovascular imaging, subclinical myocardial insults, and health policy. He leads a team of 1 Senior Research Fellow, 2 Post-Doctoral fellows, and supervises PhD students across multiple institutions. Awards include the National Heart Foundation Future Leader Fellowship and international society recognitions (FACC, FESC, FAHA). Key collaborations include NASA, Gunma University (Japan), and the ANZACT Network. His work on SUCCOUR trials and REDUCE trial (sonothrombolysis) aims to improve cardiovascular outcomes in oncology patients. He chairs editorial boards for JACC: Cardiovascular Imaging and Journal of the American Society of Echocardiography .

Travis W. Heinمشاهده پروفایل

استاد

• Medical Physiology
• Vascular Biology
• Diabetes Research
• +۳ مورد دیگر

Travis W. Hein, PhD, is a Professor in the Department of Medical Physiology at Texas A&M University's School of Medicine. His research focuses on microvascular dysfunction in diabetes, particularly in retinal and coronary microvessels, and its implications for vision loss and heart failure. He also investigates spaceflight-associated neuro-ocular syndrome (SANS) mechanisms in astronauts. Hein holds significant teaching awards, including the 2023 R. Kelly Hester Distinguished Teaching Award and membership in the Academy of Distinguished Medical Educators. Education: BA in Biology from St. Olaf College (1992), PhD in Medical Physiology from Texas A&M Health Science Center (1997). Research interests emphasize molecular mechanisms of vasomotor regulation, diabetes-induced vascular damage, and space health challenges. His work identifies therapeutic targets for microvascular diseases and explores ocular blood flow dynamics in space environments. Key publications highlight breakthroughs in retinal degeneration therapies (e.g., stanniocalcin-1), diabetic microvascular complications, and cardiovascular dysfunction mechanisms. His articles span 20+ years, demonstrating sustained contributions to vascular biology and translational medicine. Scientific awards: 2023 R. Kelly Hester Distinguished Teaching Award 2021 Elected to Academy of Distinguished Medical Educators 2017 Texas A&M Distinguished Teaching Award Grants and mentoring: Extensive NIH-funded research programs and training of graduate students/postdocs in cardiovascular and ocular physiology. Collaborates on space health initiatives through NASA partnerships. Labs/Teams: Directs Texas A&M's Microvascular Physiology Lab, focusing on translational research in diabetes and space health. Active in multidisciplinary teams addressing ocular vascular dysfunction and cardiac microcirculation.

C. Michael Gibsonمشاهده پروفایل

استاد پژوهش

• Interventional Cardiology
• Cardiovascular Research
• Clinical Trials
• +۳ مورد دیگر

C. Michael Gibson, MD is a leading interventional cardiologist, cardiovascular researcher, and educator at Harvard Medical School , where he serves as the Chief Executive Officer of the Baim Institute and PERFUSE Research Institute . These institutes have led over 1,000 studies and 5,500 peer-reviewed publications, including 144 in the New England Journal of Medicine . Key Roles: Director of Coronary Care Unit, Cardiac Catheterization Laboratory Director, Chief of Cardiology, Vice Chairman of Medicine Education: BS, MS, and MD from the University of Chicago (Phi Beta Kappa, AOA), followed by training at Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center Research Focus: Pioneered the open artery and microvasculature hypothesis in heart attacks, developed widely used coronary blood flow measures (TIMI frame count, TIMI myocardial perfusion grade), and leads virtual clinical trials like the HEARTLINE trial of the Apple Watch. Current work includes Factor XI inhibitors (milvexian) and apolipoprotein AI infusions for cardiovascular disease. Scientific Contributions: Over 148,000 citations, 659 publications, and leadership in guidelines like the Bleeding Academic Research Consortium . Notable trials include ANDexanet Alfa for anticoagulant reversal and the PEERLESS study comparing mechanical thrombectomy to thrombolysis in pulmonary embolism. Leadership: FDA Cardiorenal Panel member (2017–2021), founder of WikiDoc.org and ClinicalTrialsResults.org Media Influence: Chief Medical Correspondent for the American College of Cardiology, 435K+ social media followers Scientific Awards: Consistently ranked among the world’s most highly cited authors (Thomson Reuters, 2014–present), 50 Most Influential Voices in Healthcare (Medika Life, 2021), and Boston’s Top Doctors (multiple years).

Adam Goodwillمشاهده پروفایل

استادیار

• Cardiovascular Physiology
• Coronary Circulation
• Myocardial Function
• +۲ مورد دیگر

Adam Goodwill, Ph.D., FCVS is an Assistant Professor in the Department of Integrative Medical Sciences at Northeast Ohio Medical University (NEOMED). He previously served as Assistant Clinical Professor of Anatomy, Cell Biology & Physiology and Director of the Pre-Professional M.S. Program at Indiana University School of Medicine for a decade before relocating to Northeast Ohio in 2021. Ph.D. in Physiology and Pharmacology, West Virginia University School of Medicine (2011) B.S. in Molecular Biology/Biotechnology, Clarion University of Pennsylvania (2003) B.S. in Biology, Clarion University of Pennsylvania (2003) His research focuses on the interplay between myocardial contractile function and coronary blood flow regulation, particularly how oxygen demand and delivery become dysregulated in cardiovascular diseases. The laboratory employs a top-down approach, starting with in vivo models and progressing to molecular analysis, aiming to identify therapeutic targets for cardiovascular disorders. Key research themes from his publications include: Investigation of sodium-glucose cotransporter-2 inhibition in myocardial ischemia GLP-1 receptor activation effects on cardiac efficiency in obese models Role of KV1 channels in coronary blood flow regulation Adipose tissue dysfunction in disease pathogenesis Scientific recognitions include awards from the American Physiological Society (Teaching and Cardiovascular Sections) and the Society for Experimental Biology and Medicine's Burton E. Sobel Award. He has presented at major conferences including Experimental Biology, Korean Society of Heart Failure, and American Heart Association Scientific Sessions. Dr. Goodwill serves on editorial boards for Frontiers in Cardiovascular Therapeutics and Scientific Reports , and teaches courses in Cardiovascular, Pulmonary and Renal (CPR) systems as well as Gastrointestinal-Reproductive-Endocrine (GRE) systems at NEOMED.

• Cardiology
• Cardiovascular Imaging
• Health Economics
• +۳ مورد دیگر

Dr. Faraz Pathan is a Senior Lecturer at Sydney Medical School and a cardiologist specializing in cardiovascular imaging. Based at Nepean Hospital, he serves as Head of Cardiac Imaging and Cardiac Research within the Cardiology Department. University of New South Wales (2006), First Class Honours His research focuses on precision phenotyping of cardiovascular pathophysiology using Cardiac Magnetic Resonance (CMR), atrial strain as a cardiovascular outcome predictor, appropriate cardiac imaging use, heart failure readmission reduction, and health economics applications in cardiology. Key trends in his 2021-2025 publications include multimodality imaging techniques, atrial strain analysis, chemotherapy-related cardiotoxicity, and obesity-related cardiovascular imaging challenges. Collaborative projects span institutions like Goethe Institute Frankfurt and Menzies Institute for Medical Research. Scientific recognition includes the Ten of the Best research award from Menzies Institute for Medical Research. Grants highlight his work in microvascular restoration (REDUCE trial), obesity-cardiovascular interactions, and cardiac inflammation mapping. He leads a nine-researcher team in echocardiography quality improvement, atrial strain analysis, heart failure protocols, and health economics studies. International collaborations with Goethe Institute Frankfurt and Menzies Institute for Medical Research demonstrate his global research impact, particularly in experimental cardiovascular imaging and translational studies.

• Cardiovascular Medicine
• Infectious Diseases
• Medical Informatics
• +۴ مورد دیگر

Dr. Kevin O'Gallagher is a Senior Clinical Lecturer at SCMMS Denmark Hill, specializing in cardiovascular medicine and public health. His research focuses on heart failure mechanisms, racial/ethnic disparities in cardiovascular diseases, and the application of natural language processing (NLP) in medical diagnostics. He leads multiple projects funded by the MRC and British Heart Foundation (BHF), including investigations into coronary microvascular dysfunction and HFpEF pathophysiology. Recent work includes studies on aortic stenosis disparities, CREST model validation for cardiac arrest outcomes, and the impact of COVID-19 on cardiovascular health. Dr. O'Gallagher's interdisciplinary approach integrates clinical cardiology with advanced analytics, addressing both clinical and health equity challenges. He has contributed to peer-reviewed journals such as JACC: Cardiovascular Interventions and European Heart Journal Digital Health, with over 574 citations. His work aligns with UN Sustainable Development Goals related to good health and well-being (SDG 3). Key projects include: CORONARY MICROVASCULAR DYSFUNCTION (MRC-funded, 2023-2028) PRIME: Prevention of Recurrent Ischaemic Events (GSTT, 2024-2025) BHF Pump-Prime Grant for HFpEF research (2024) NLP-based AI for HFpEF detection (BHF, 2023-2025) Collaborative networks span institutions globally, addressing topics like NLP-driven healthcare equity and pandemic-related cardiac complications.

• Structural Heart Disease
• Transcatheter Valve Therapy
• Interventional Cardiology
• +۲ مورد دیگر

Dr. Jubin P Joseph is a Clinical Assistant Professor of Medicine at the Keck School of Medicine of the University of Southern California and serves as Director of Structural Interventions in the Cardiac & Vascular Institute. An interventional cardiologist specializing in structural heart disease, he leads advanced transcatheter valve therapies and clinical research initiatives at USC. His educational journey includes: Undergraduate studies at Cambridge University (2005) Medical degree from Oxford University (2008) Internal medicine and cardiology training in England PhD in invasive physiology research from St Thomas' Hospital, London Advanced structural intervention fellowship at Oxford University Hospitals Specialized training at Cedars-Sinai Medical Center (2020-2022) Dr. Joseph's research centers on structural heart disease mechanisms and transcatheter interventions, with particular focus on valve pathophysiology, hemodynamic assessments, and device innovation. His clinical expertise spans transcatheter aortic/mitral/tricuspid valve replacements, MitraClip procedures, left atrial appendage occlusion, and congenital defect closures. He integrates cardiovascular physiology with structural interventions to optimize patient outcomes in complex valve disease. His publication record reveals consistent advancement in transcatheter valve therapy, emphasizing hemodynamic outcomes, imaging guidance, and novel device applications. Recent work demonstrates leadership in TAVR optimization, mitral repair techniques, and physiological assessment during interventions, reflecting his dual commitment to clinical innovation and scientific rigor. Major recognitions include: Peel and Rothwell Jackson Postgraduate Fellowship (2020-2021) European Society of Cardiology's Cardiologist of Tomorrow (2014-2017) Royal College of Surgeons' Preiskel Prize (2008) Multiple medical education travel awards (2008) Cambridge University's Preparing for Patients Prize (2003) As a clinical investigator, Dr. Joseph actively contributes to national multicenter trials while directing structural interventions at USC's Cardiac & Vascular Institute. His team pioneers emerging transcatheter therapies through rigorous physiological assessment and device evaluation, with ongoing research in microvascular dysfunction and next-generation valve technologies. The structural interventions program under his leadership focuses on complex valve disease management, combining cutting-edge transcatheter approaches with comprehensive physiological evaluation to advance structural heart care.

• Cardiovascular Medicine
• Coronary Microvascular Dysfunction
• Myocardial Infarction Pathophysiology
• +۳ مورد دیگر

Dr. Stuart Hood is an Honorary Senior Lecturer at the University of Glasgow, affiliated with the School of Cardiovascular & Metabolic Health and the Cardiology Department at the Royal Alexandra Hospital. His expertise focuses on coronary microvascular dysfunction, myocardial infarction pathophysiology, and interventional cardiology. He has contributed to numerous studies on fractional flow reserve (FFR), stent optimization, and coronary artery disease management. Research interests include the interplay between coronary microvascular function and atherosclerosis, as well as outcomes in patients with non-obstructive coronary arteries. His work integrates clinical trials (e.g., CorMicA, TARGET-FFR) and imaging techniques (e.g., MRI, cardiac CT) to improve diagnostic accuracy and patient care. Key themes in his publications address post-percutaneous coronary intervention (PCI) outcomes, risk stratification in acute myocardial infarction, and the role of systemic microvascular dysfunction in angina. His articles highlight advancements in PCI optimization, prognostic biomarkers for myocardial infarction, and the impact of diabetes on coronary thrombus formation. Dr. Hood collaborates with institutions like the British Cardiovascular Intervention Society and has presented at major conferences such as ACC.18 and the British Society of Cardiovascular Magnetic Resonance. No scientific awards or grants are explicitly listed in the provided materials. His academic contributions are centered on clinical research and translational cardiology, with a focus on improving therapeutic strategies for coronary artery disease and post-infarction care.

• Acute coronary syndrome pathophysiology and treatment
• Coronary microvasculature
• Platelet physiology
• +۲ مورد دیگر

Professor James Cotton is a Clinical Interventional Cardiologist at the Heart and Lung Centre, New Cross Hospital, and holds the position of Professor of Cardiology in the Faculty of Science and Engineering at the University of Wolverhampton. He has an ORCID identifier 0000-0001-6548-2723 and has been active in cardiovascular research and clinical practice since at least 2003. MBBS from University of London (1998) MD from University of London (2000) MRCP from Royal College of Physicians (London) His research focuses on acute coronary syndrome pathophysiology , coronary microvasculature , platelet physiology , transcatheter aortic valve implantation , and pathophysiology of aortic aneurysm formation . Recent work explores therapeutic microRNA targeting, revascularization completeness, and novel predictors for microvascular reperfusion. Key publication trends include interventional cardiology (TAVI, stent techniques), myocardial infarction (reperfusion strategies, strain analysis), molecular cardiology (microRNA dysregulation), and clinical trial outcomes in cardiovascular interventions. MRCP from Royal College of Physicians, London As an educator, he mentors junior doctors, delivers teaching sessions for University of Birmingham medical students, and serves as appraiser/mentor for Royal Wolverhampton NHS Trust clinicians. His research has received funding from multiple sources including the Rotha Abraham Bequest and Wolverhampton Healthcare Tripartite Grant Committee . He leads clinical research at the Heart and Lung Centre , New Cross Hospital, and collaborates with institutions like the University of Birmingham.